商品名：Liquaemin and Hepalean (Canada)
Anticoagulant. Heparin produces its action by increasing antithrombin III–mediated inhibition of synthesis and activity of factor Xa. Heparin differs from low-molecular-weight heparin (LMWH) by an equal anti-factor Xa/anti-factor IIa ratio. Heparin has a ratio of 1 : 1, but the LMWHs have ratios of 2 : 1 or higher. In people, there is an advantage of LMWH over conventional heparin because the LMWHs have longer half-lives and less frequent administration is needed. However, this may not be an advantage for dogs and cats. See the description Heparin Sodium 361 H of LMWH for more information (eno
Heparin is administered to prevent and treat hypercoagulability disorders and prevent coagulation disorders such as thromboembolism, venous thrombosis, disseminated intravascular coagulopathy (DIC), and pulmonary thromboembolism. Use in specific situations in animals is primarily anecdotal or derived from the clinical experience in people. No outcome-based studies to evaluate efficacy have been published to support specific guidelines for therapy. Use for prevention of thrombosis in canine patients with immune-mediated hemolytic anemia has not been effective (300 units/kg q6h). In horses, it i
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
肝素鈉是高警訊藥物；物種、疾病目的、預防或治療、精確成品與濃度、保存劑、容器、給藥情境、檢驗方法、採樣時點、目標與調整權限尚未形成可執行的完整獸醫契約，因此 runtime、計算器、處方輸出與自動交互作用一律封鎖。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。